Subtype
Malignant Urinary System Neoplasm
CI-CAN-00001187Explore in graph →
887 active trials28 approved drugs109 evidence items
- NCIt
- C9297
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001187Explore in graph →
Clinical trials
3,851 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (556)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05885204 | RARC vs LRC in A Multicenter Cohort Study | unknown | — | 3,815 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jun 1, 2023 |
| clinicaltrials |
| NCT05823246 | Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma | unknown | Phase 2 | 66 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 26, 2023 | clinicaltrials |
| NCT04948528 | Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for Upper Tract Urothelial Carcinoma Detection | unknown | — | 490 | AnchorDx Medical Co., Ltd.INDUSTRY | 1 | May 24, 2023 | clinicaltrials |
| NCT05865730 | A Study of Oncobax®-AK in Patients With Advanced Solid Tumors | unknown | Phase 2 | 122 | EverImmuneINDUSTRY | 2 | May 19, 2023 | clinicaltrials |
| NCT05856825 | Long-Term Outcomes of Robot-Assisted Radical Cystectomy: A Real-World Study | unknown | — | 4,500 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | May 12, 2023 | clinicaltrials |
| NCT05843305 | A Study of BPI-452080 in Subjects With Solid Tumors | unknown | Phase 1 | 87 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT04391790 | MOdified Urinary Conduit to Lower Strictures After radIcal Cystectomy(MOSAIC) | unknown | N/A | 300 | Jørgen Bjerggaard JensenOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05833997 | Safety Analysis and Oncological Outcomes in HoLERT vs TURBT | unknown | N/A | 100 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05285579 | Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer(ANGIOCOR) | unknown | — | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05816642 | Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma | unknown | N/A | 500 | RenJi HospitalOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT01675219 | Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9) | unknown | Phase 3 | 400 | Turku University HospitalOTHER_GOV | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05798455 | Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Tabriz University of Medical SciencesOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05790122 | Safety and Efficacy of Sutureless Zero Ischemia Laparoscopic Tumor Enucleation for T1 Stage Renal Carcinoma | unknown | — | 146 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03280667 | Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma(KEYPAD) | unknown | Phase 2 | 59 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05084586 | Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation | unknown | N/A | 100 | Ankara Training and Research HospitalOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05787938 | Role of MRI in Assessment of the Urinary Bladder Wall Post Transurethral Tumor Resection | unknown | — | 58 | Assiut UniversityOTHER | 0 | Mar 28, 2023 | clinicaltrials |
| NCT05785052 | Biomarkers of Renal Cancer(BRC) | unknown | — | 1,000 | Biorek S.R.L.INDUSTRY | 2 | Mar 27, 2023 | clinicaltrials |
| NCT04543110 | Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC(RADIANT) | unknown | Phase 2 | 16 | Ottawa Hospital Research InstituteOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT05775874 | A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC | unknown | Phase 2 | 80 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT05767528 | Clinical Study of Neoadjuvant Therapy Outcome Prediction of Muscle-invasive Bladder Cancer Based on PTC Drug Sensitivity Detection | unknown | — | 40 | Chinese PLA General HospitalOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05732857 | Valveless Trocar Versus Standard Trocar in Robot-assisted Complex Partial Nephrectomy | unknown | N/A | 66 | Regina Elena Cancer InstituteOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT04799847 | Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine | unknown | Phase 1 / Phase 2 | 161 | LintonPharm Co.,Ltd.INDUSTRY | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05723991 | Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma | unknown | Phase 4 | 36 | Chunguang yang (101937)OTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05643807 | Bladder Washing Cytology for Detection of Urothelial Carcinoma Using Catheter or Flexible Cystoscope: Which is Better?(BWash) | unknown | N/A | 414 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT05508568 | A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer | unknown | — | 650 | Arquer Diagnostics LtdINDUSTRY | 1 | Feb 1, 2023 | clinicaltrials |
| NCT05705583 | A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma | unknown | — | 100 | Zhejiang Cancer HospitalOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05697224 | Aschistosoma Haematobiumspecific microRNAas a Tumor Marker for Early Diagnosis and Prognosis of Bilharzial Bladder Cancer in Eygpt | unknown | N/A | 50 | Sohag UniversityOTHER | 0 | Jan 25, 2023 | clinicaltrials |
| NCT05638256 | 68Ga-labeled NY104 PET Imaging in Patients | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04730219 | Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma | unknown | Phase 2 | 48 | Tianjin Medical University Second HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05456074 | Integrative Molecular Characterization Of MiT Family Translocation Renal Cell Carcinomas (IMCOR)(IMCOR) | unknown | — | 600 | Institut de cancérologie Strasbourg EuropeOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT05005195 | Yorkshire Kidney Screening Trial(YKST) | unknown | N/A | 5,850 | University of LeedsOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05480735 | EffectiveNess of a Multimodal preHAbilitation Program in patieNts With Bladder canCEr Undergoing Cystectomy(ENHANCE) | unknown | N/A | 154 | The Netherlands Cancer InstituteOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT03529890 | Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder(RACE IT) | unknown | Phase 2 | 33 | Technical University of MunichOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05564897 | Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer | unknown | Phase 2 | 25 | Zhejiang Cancer HospitalOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05038657 | Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).(AURORA) | unknown | Phase 2 | 36 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT04913025 | REduced Frequency ImmuNE Checkpoint Inhibition in Cancers(REFINE) | unknown | Phase 2 | 160 | University College, LondonOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT04262427 | The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma(CAPER) | unknown | Phase 1 / Phase 2 | 21 | The Christie NHS Foundation TrustOTHER | 1 | Aug 23, 2022 | clinicaltrials |
| NCT05440045 | A Clinical Study of 6MW3211 in Patients With Renal Cancer | unknown | Phase 2 | 30 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 0 | Aug 17, 2022 | clinicaltrials |
| NCT05243173 | Biomarkers of Response to Systemic Treatments in FH-deficient RCC | unknown | — | 100 | RenJi HospitalOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT05503563 | A Proposed Tetra-modal Treatment Protocol for Muscle Invasive Urothelial Carcinoma of the Urinary Bladder | unknown | — | 50 | Assiut UniversityOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT03844256 | A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study(CRIMI) | unknown | Phase 1 / Phase 2 | 50 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT03934827 | MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour(MICROBIOME) | unknown | Phase 1 | 120 | Imperial College LondonOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT04282876 | Influence of Hormone Treatment in Radiation Therapy for Bladder Cancer | unknown | — | 60 | Aarhus University HospitalOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT05485883 | Tislelizumab Plus Lenvatinib in Stage III-IV RCC(TILUR) | unknown | Phase 2 | 20 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT05486871 | Oncological and Functional Outcomes of Laparoscopic Partial Nephrectomy in Renal Cell Carcinoma Stages T1 Versus T2a: Prospective Comparative Study. | unknown | N/A | 30 | Sohag UniversityOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05488353 | A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma | unknown | Phase 4 | 48 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 4, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jun 1, 2023source: clinicaltrials